WO2024256632 - PHARMACEUTICAL FORMULATIONS OF AN AMYLIN RECEPTOR AGONIST AND A GLP-1 RECEPTOR AGONIST COMPRISING A CYCLODEXTRIN
National phase entry:
Publication Number
WO/2024/256632
Publication Date
19.12.2024
International Application No.
PCT/EP2024/066541
International Filing Date
14.06.2024
Title **
[English]
PHARMACEUTICAL FORMULATIONS OF AN AMYLIN RECEPTOR AGONIST AND A GLP-1 RECEPTOR AGONIST COMPRISING A CYCLODEXTRIN
[French]
FORMULATIONS PHARMACEUTIQUES UN AGONISTE DU RÉCEPTEUR DE L'AMYLINE ET UN AGONISTE DU RÉCEPTEUR GLP-1 COMPRENANT UNE CYCLODEXTRINE
Applicants **
NOVO NORDISK A/S
Inventors
KJELDSEN, Benjamin, Troest
HANSEN, Rosa, Rebecca, Erritzøe
CHRISTOFFERSEN, Stig
Priority Data
23179381.1
15.06.2023
EP
23180629.0
21.06.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2749 | |
| EPO | Filing, Examination, Granting | 11197 | |
| Japan | Filing, Examination, Granting | 2207 | |
| South Korea | Filing, Examination, Granting | 2146 | |
| USA | Filing, Examination, Granting | 5790 |
Total:
24,089
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Disclosed herein is a preserved liquid pharmaceutical formulation comprising an amylin receptor agonist, a GLP-1 receptor agonist, a cyclodextrin comprising hydroxypropyl substitutions and one or more preservatives. Said co-formulation may be used for the medical treatment of subjects with overweight or obesity, with or without associated co-morbidities; diabetes, with or without associated comorbidities; and cardiovascular diseases.[French]
L'invention divulgue une formulation pharmaceutique liquide préservée comprenant un agoniste du récepteur de l'amyline, un agoniste du récepteur GLP-1, une cyclodextrine comprenant des substitutions d'hydroxypropyle et un ou plusieurs conservateurs. Ladite coformulation peut être utilisée pour le traitement médical de sujets atteints de surpoids ou d'obésité, avec ou sans comorbidités associées; le diabète, avec ou sans comorbidités associées; et des maladies cardiovasculaires.